News | Stents Peripheral | April 28, 2017

New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent

Biotronik's bare metal stent proves effective and versatile as standalone and in combination with drug-coated balloon

New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the 12-month results of the BIOFLEX PEACE all-comers registry. The findings were presented this week at the Charing Cross Symposium, April 25-28 in London. Outcomes of the BIOLUX 4EVER study were also presented on the main stage, revealing 12-month results numerically comparable to drug-eluting stents (DES) when the Pulsar-18 was used in combination with the Passeo-18 Lux drug-coated balloon (DCB).

The 12-month results from the BIOFLEX PEACE All-Comers Registry revealed findings for the first time for the entire patient cohort for the Pulsar-18 in the treatment of femoral popliteal lesions in a real-world setting. During the presentation at the Charing Cross Symposium, lead investigator Michael Lichtenberg, M.D., highlighted the 73.6 percent primary patency and 96.2 percent freedom from clinically driven target lesion revascularization (fTLR) in 164 patients. “These results are in line with already published data for the Pulsar stent from controlled trials, thus confirming the stent’s efficacy for a broader range of patients and lesions,” commented Lichtenberg, Vascular Center Clinic, Arnsberg, Germany.

In the BIOLUX 4EVER trial, physicians used the combination of the Pulsar-18 BMS and the Passeo-18 Lux DCB to treat superficial femoral artery (SFA) lesions. Koen Deloose, M.D., AZ Sint-Blasius, Dendermonde, Belgium presented the full 12-month (395 days) outcomes of this trial, with 89.9 percent primary patency and 91.6 percent fTLR in a cohort of 120 patients.

“The 12-month outcomes of the BIOLUX 4EVER trial indicate the value of a combined approach that provides physicians with more options and versatility when treating SFA lesions while achieving DES-like results,” commented Deloose. “While DES is limited by the need to fully cover the lesion with a stent and fully treat the lesion with paclitaxel, the new combination approach of a DCB and BMS means that there is now the freedom to determine how much support is necessary based on each vessel’s unique anatomy and lesion characteristics for a more tailored approach. Following full lesion coverage with the DCB, if full lesion stenting is deemed necessary, we have the results of BIOLUX 4EVER to give physicians the confidence of a good outcome; should the physician decide to minimize the metal burden, partial (focal) stenting can be used, which is not an option with DES.”

For more information: www.biotronik.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init